Repligen Co. (NASDAQ:RGEN) Stake Raised by HighTower Advisors LLC

HighTower Advisors LLC increased its holdings in Repligen Co. (NASDAQ:RGENGet Rating) by 1.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,652 shares of the biotechnology company’s stock after acquiring an additional 197 shares during the period. HighTower Advisors LLC’s holdings in Repligen were worth $3,330,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Cerity Partners LLC lifted its stake in Repligen by 34.0% in the 1st quarter. Cerity Partners LLC now owns 1,597 shares of the biotechnology company’s stock worth $301,000 after acquiring an additional 405 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its stake in Repligen by 1,629.1% in the 1st quarter. Steward Partners Investment Advisory LLC now owns 951 shares of the biotechnology company’s stock worth $179,000 after acquiring an additional 896 shares in the last quarter. Swiss National Bank lifted its stake in Repligen by 8.0% in the 1st quarter. Swiss National Bank now owns 124,200 shares of the biotechnology company’s stock worth $23,361,000 after acquiring an additional 9,200 shares in the last quarter. Van ECK Associates Corp lifted its stake in Repligen by 59.5% in the 1st quarter. Van ECK Associates Corp now owns 6,495 shares of the biotechnology company’s stock worth $1,222,000 after acquiring an additional 2,422 shares in the last quarter. Finally, Lmcg Investments LLC purchased a new stake in Repligen in the 1st quarter worth about $525,000. 90.17% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Performance

Shares of NASDAQ RGEN opened at $210.34 on Monday. The firm has a market cap of $11.67 billion, a price-to-earnings ratio of 75.94, a P/E/G ratio of 9.94 and a beta of 1.07. The business’s 50-day simple moving average is $204.92 and its 200-day simple moving average is $179.82. Repligen Co. has a 52 week low of $137.21 and a 52 week high of $327.32.

Repligen (NASDAQ:RGENGet Rating) last issued its quarterly earnings data on Tuesday, August 2nd. The biotechnology company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.19. The business had revenue of $207.63 million for the quarter, compared to analyst estimates of $189.06 million. Repligen had a return on equity of 11.18% and a net margin of 20.47%. The firm’s revenue for the quarter was up 27.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.79 EPS. As a group, equities research analysts forecast that Repligen Co. will post 3.18 earnings per share for the current year.

Insider Activity at Repligen

In related news, CEO Anthony Hunt sold 24,802 shares of the stock in a transaction that occurred on Thursday, July 21st. The stock was sold at an average price of $200.00, for a total transaction of $4,960,400.00. Following the completion of the sale, the chief executive officer now owns 194,667 shares in the company, valued at approximately $38,933,400. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CEO Anthony Hunt sold 24,802 shares of the stock in a transaction that occurred on Thursday, July 21st. The stock was sold at an average price of $200.00, for a total transaction of $4,960,400.00. Following the completion of the sale, the chief executive officer now owns 194,667 shares in the company, valued at approximately $38,933,400. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Jon Snodgres sold 2,000 shares of the stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $220.00, for a total value of $440,000.00. Following the sale, the chief financial officer now owns 37,187 shares of the company’s stock, valued at approximately $8,181,140. The disclosure for this sale can be found here. Insiders sold a total of 43,697 shares of company stock worth $9,621,550 in the last 90 days. 1.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

RGEN has been the topic of several research reports. SVB Leerink upped their target price on Repligen from $220.00 to $250.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 3rd. UBS Group initiated coverage on Repligen in a research report on Wednesday, July 20th. They issued a “buy” rating and a $213.00 target price on the stock. KeyCorp upped their target price on Repligen from $245.00 to $260.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 3rd. Finally, Stephens upped their target price on Repligen from $220.00 to $275.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 3rd. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $276.00.

Repligen Company Profile

(Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Featured Articles

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGENGet Rating).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.